BRIEF-Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

Reuters

25 Mar

BRIEF-Axsome <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder <a href="https://laohu8.com/S/ADHD">$(ADHD)$</a> Achieves Primary Endpoint

March 25 (Reuters) - Axsome Therapeutics Inc AXSM.O:

AXSOME THERAPEUTICS ANNOUNCES FOCUS PHASE 3 TRIAL OF SOLRIAMFETOL IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ACHIEVES PRIMARY ENDPOINT
AXSOME THERAPEUTICS INC: WELL TOLERATED WITH SAFETY PROFILE GENERALLY CONSISTENT WITH PRIOR SOLRIAMFETOL TRIALS
AXSOME THERAPEUTICS INC: STATISTICALLY SIGNIFICANT REDUCTION IN OVERALL ADHD DISEASE SEVERITY AS MEASURED BY CGI-S SCORE COMPARED TO PLACEBO
AXSOME THERAPEUTICS : STATISTICALLY SIGNIFICANT IMPROVEMENT IN ADHD SYMPTOMS AS MEASURED BY AISRS TOTAL SCORE COMPARED TO PLACEBO

Source text: ID:nGNX7rXL64

Further company coverage: AXSM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522021451"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522021451\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522021451?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-25 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522021451","market":"nz","top_or_hot":-1,"title":"BRIEF-Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder <a href=\"https://laohu8.com/S/ADHD\">$(ADHD)$</a> Achieves Primary Endpoint</title></head><body><p><span>March 25 (Reuters)</span><span> - </span>Axsome Therapeutics Inc <span>AXSM.O</span>:</p><ul><li><p>AXSOME THERAPEUTICS ANNOUNCES FOCUS PHASE 3 TRIAL OF SOLRIAMFETOL IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ACHIEVES PRIMARY ENDPOINT</p></li><li><p>AXSOME THERAPEUTICS INC: WELL TOLERATED WITH SAFETY PROFILE GENERALLY CONSISTENT WITH PRIOR SOLRIAMFETOL TRIALS</p></li><li><p>AXSOME THERAPEUTICS INC: STATISTICALLY SIGNIFICANT REDUCTION IN OVERALL ADHD DISEASE SEVERITY AS MEASURED BY CGI-S SCORE COMPARED TO PLACEBO</p></li><li><p>AXSOME THERAPEUTICS : STATISTICALLY SIGNIFICANT IMPROVEMENT IN ADHD SYMPTOMS AS MEASURED BY AISRS TOTAL SCORE COMPARED TO PLACEBO</p></li></ul><p>Source text: <span>ID:nGNX7rXL64</span></p><p>Further company coverage: <span>AXSM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-25 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder <a href=\"https://laohu8.com/S/ADHD\">$(ADHD)$</a> Achieves Primary Endpoint</title></head><body><p><span>March 25 (Reuters)</span><span> - </span>Axsome Therapeutics Inc <span>AXSM.O</span>:</p><ul><li><p>AXSOME THERAPEUTICS ANNOUNCES FOCUS PHASE 3 TRIAL OF SOLRIAMFETOL IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ACHIEVES PRIMARY ENDPOINT</p></li><li><p>AXSOME THERAPEUTICS INC: WELL TOLERATED WITH SAFETY PROFILE GENERALLY CONSISTENT WITH PRIOR SOLRIAMFETOL TRIALS</p></li><li><p>AXSOME THERAPEUTICS INC: STATISTICALLY SIGNIFICANT REDUCTION IN OVERALL ADHD DISEASE SEVERITY AS MEASURED BY CGI-S SCORE COMPARED TO PLACEBO</p></li><li><p>AXSOME THERAPEUTICS : STATISTICALLY SIGNIFICANT IMPROVEMENT IN ADHD SYMPTOMS AS MEASURED BY AISRS TOTAL SCORE COMPARED TO PLACEBO</p></li></ul><p>Source text: <span>ID:nGNX7rXL64</span></p><p>Further company coverage: <span>AXSM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q804P:1","article_id":"2522021451","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522021451","pubTimestamp":1742903113,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary EndpointMarch 25 (Reuters) - Axsome Therapeutics","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4007":"制药","AXSM":"Axsome Therapeutics, Inc."},"translate_title":"简介-Axsome Therapeutics宣布Solriamfetol治疗成人注意力缺陷多动障碍(ADHD)的FOCUS 3期试验达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":0.9},"content_text":"BRIEF-Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder $(ADHD)$ Achieves Primary EndpointMarch 25 (Reuters) - Axsome Therapeutics Inc AXSM.O:AXSOME THERAPEUTICS ANNOUNCES FOCUS PHASE 3 TRIAL OF SOLRIAMFETOL IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ACHIEVES PRIMARY ENDPOINTAXSOME THERAPEUTICS INC: WELL TOLERATED WITH SAFETY PROFILE GENERALLY CONSISTENT WITH PRIOR SOLRIAMFETOL TRIALSAXSOME THERAPEUTICS INC: STATISTICALLY SIGNIFICANT REDUCTION IN OVERALL ADHD DISEASE SEVERITY AS MEASURED BY CGI-S SCORE COMPARED TO PLACEBOAXSOME THERAPEUTICS : STATISTICALLY SIGNIFICANT IMPROVEMENT IN ADHD SYMPTOMS AS MEASURED BY AISRS TOTAL SCORE COMPARED TO PLACEBOSource text: ID:nGNX7rXL64Further company coverage: AXSM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}